IDEXX will broaden its Cancer Dx™ Panel to include canine mast cell tumor detection in North America beginning mid-2026, complementing the existing lymphoma test already used by over 5,500 practices to identify disease up to eight months before clinical signs appear. The mast cell tumor assay will be provided at no extra cost, with results delivered in 2–3 days in the U.S. and 2–4 days in Canada, using identical specimen requirements and workflows. Combined with the rollout of fine-needle aspiration cytology on the inVue Dx™ Cellular Analyzer in late Q4 2025, these diagnostics will cover more than one-third of all canine cancers, enabling veterinarians to screen at-risk dogs (those aged seven years and older, or high-risk breeds from age four) during routine visits and to obtain rapid, in-clinic confirmation when suspicious masses are detected.

The ImageVue™ DR50 Plus system, now available in the U.S. and Canada, delivers high-definition radiographic images at up to 25% lower radiation dose versus the prior IDEXX DR50 model and up to 60% less than competing veterinary systems. Featuring AI-driven image optimization, automated exposure protocols and irradiated side sampling to reduce retakes, the platform supports both 14"×17" and new 17"×17" panels. Integrated into IDEXX Web PACS™, it offers centralized access, AI-powered hanging protocols and vertebral heart score calculations, while the embedded telemedicine link to 160+ board-certified specialists cuts case-submission clicks by over 45%, streamlining diagnosis and promoting staff safety in clinics where 75% of technicians are women of childbearing age.

Effective May 12, 2026, Michael (Mike) Erickson, PhD, will assume the role of President and CEO, joining the Board at the same time, while current CEO Jay Mazelsky will become Executive Chair and retire following the May 2027 annual meeting. Dr. Erickson brings nearly two decades of healthcare technology leadership at IDEXX—having led diagnostics, software, strategy and corporate accounts since joining in 2011—and prior McKinsey & Company experience advising top pharmaceutical and biotech firms. The Board praised his deep business knowledge and innovation expertise as critical to sustaining IDEXX’s growth in a portfolio spanning pet diagnostics, water and milk safety, and software solutions across 175+ countries with some 11,000 employees.